The collapse of the mRNA narrative was inevitable. Despite massive government subsidies, favorable media treatment, and pharmaceutical profits measured in billions, mRNA vaccines failed to live up to the hype. Rapidly waning immunity, variant evasion, and serious safety concerns have become too big to ignore.
Secretary Robert F. Kennedy Jr.’s cancellation of BARDA’s mRNA contracts was more than symbolic. It was the first real policy course correction in a vaccine ecosystem that had drifted from science into speculative biotech fantasy. Now, with the door closing on RNA-based shortcuts, the urgent question becomes: what comes next?
The answer isn’t in gimmicks. It’s in biologically sound, rigorously tested technologies that can accomplish two essential objectives:
Induce broad, long-lasting immunity—ideally across entire virus families.
Stop transmission at the point of entry—especially the respiratory mucosa.
Here’s what the next era of vaccine technology must focus on:
Risk Factor - Dr. An…
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.